Genetic Testing in Cancer Therapeutics: Fig. 1.

Genetic testing in cancer therapeutics.

A major challenge to physicians administering drugs with a low therapeutic index, such as chemotherapeutic agents, is the variability in drug disposition and clearance. This variability accounts for the wide interpatient response to conventional doses of antineoplastic agents. Currently, most dosing regimens are based on body weight or surface area, with the decision for dose modifications typi...

Fig. 1

Targeting checkpoint kinase 1 in cancer therapeutics.

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Our knowledge of the biochemical nature of checkpoint regulation during an unperturbed cell cycle and following DNA damage has expanded tremendously over the past decade. We now know that dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumor progressi...

XWH - 11 - 1 - 0127 TITLE : Chemical strategy to translate genetic / epigenetic mechanisms to breast cancer therapeutics

Modular Cre/lox System and Genetic Therapeutics for Colorectal Cancer

The Cre/lox system is a powerful tool for targeting therapeutic effectors in a wide variety of human disorders. I review a Cre/lox Wnt-targeted system that has shown promise against Wnt-positive colorectal cancer cell lines. In addition to Wnt-specific targeting of cell death inducers, the modular nature of this gene therapy model system can be exploited by designing positive and negative feedb...